Generic Name and Formulations:
Ciclesonide 50mcg/spray; aqueous nasal spray.
Indications for OMNARIS:
Treatment of seasonal allergic rhinitis in patients ≥6yrs old and perennial allergic rhinitis in patients ≥12yrs old.
2 sprays in each nostril once daily (200mcg/day).
Seasonal allergic rhinitis: <6yrs: not recommended. ≥6yrs: 2 sprays in each nostril once daily (200mcg/day).
Avoid use in patients with recent nasal ulcers/surgery/trauma until healed. Potential worsening of active tuberculosis; fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. If exposed to measles or chickenpox, consider immunoglobulin prophylactic therapy. If adrenal suppression exists following systemic corticosteroid therapy, replacement with topical steroids may exacerbate symptoms of adrenal insufficiency. Monitor for hypercorticism and HPA axis suppression (if occur discontinue slowly), and for candida infection and other nasal mucosal changes. Monitor for vision changes or with history of increased intraocular pressure, glaucoma and/or cataracts. Monitor for growth suppression in children. Avoid spraying eyes, or directly onto the nasal septum. Reevaluate if no improvement after 2 weeks (for seasonal allergic rhinitis) and 5 weeks (for perennial allergic rhinitis). Pregnancy (Cat. C). Nursing mothers.
May be potentiated by ketoconazole.
Headache, epistaxis, nasopharyngitis, ear pain, pharyngolaryngeal pain.
Nasal spray (pump)—12.5g (120 sprays)
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|